Trial intelligence / Profile preview

PK Study of SR-T100 Gel in Actinic Keratosis

NCT02029066Phase 1Completed

Sponsor
G&E Herbal Biotechnology
Start
Nov 2013
Primary completion
Feb 2014
Modality
Transdermal Patches, Hydrogel Systems, Small Molecules
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of SR-T100 in actinic keratosis (AK), sponsored by G&E Herbal Biotechnology. Primary endpoint: Plasma solamargine levels at 33 days. Started Nov 2013; status: completed.

02

Drugs

SR-T100
03

Conditions

actinic keratosis (AK)

Beyond the preview

Go deeper on NCT02029066.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02029066.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call